One of the significant advantages of NANOSPRESSO-NL is its potential to create medicines for rare diseases, conditions often overlooked by the pharmaceutical industry due to the low demand for their treatments. The device focuses on mRNA medicines, primarily used for children with metabolic diseases. These molecules can instigate specific processes at the cellular level, such as halting or producing a particular protein.
NANOSPRESSO is funded by the Dutch Research Agenda (NWA) ORC 2020/21 program. For more information about our partners, funding, and legal notices, please visit our contact page and follow us on social media.